Skip to main content
Erschienen in: Journal of Cancer Education 4/2012

01.12.2012 | Editorial

What Do We Know 40 Years After Nixon Declared the ‘War on Cancer’? On the Origin, Prevention and Treatment of Cancer

Erschienen in: Journal of Cancer Education | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Abstract

Evolutionary principles suggested by Darwin and Wallace some 150 years ago can provide insights into the origins of cancer. Moreover, they can form a basis for answering the question implicitly posed when Nixon declared the war on cancer in 1971: Can we actually ‘cure’ cancer? As explained lucidly by Greaves in 2001, necessary keys to evolution and thus for the origin of species, including ours, are changes of genes or mutations; but changes of genes are also necessary links in the causal chains which lead to cancer. In effect, cancer is therefore, according to Greaves, an ‘evolutionary legacy’. Intriguingly, the realization that cancer is a consequence of changes in genes which are conditiones sine qua non for evolution suggests a mutation paradox on an evolutionary scale: in individuals, mutations may have devastating adverse health effects, including cancer. Populations, however, as a whole can be expected to benefit ultimately from changes of genes to better adapt to environmental challenges. On the basis of premises from evolution theory, it remains for us to interweave growing insights into evolutionary principles with realistic objectives for the primary prevention of and, where the latter fails, coexistence with cancer so that what we do for patients can become more of an art rather than a war.
Literatur
1.
Zurück zum Zitat Dobzhansky T (1937) Nothing in biology makes sense except in light of evolution. Am Biol Teach 35:125–129CrossRef Dobzhansky T (1937) Nothing in biology makes sense except in light of evolution. Am Biol Teach 35:125–129CrossRef
2.
Zurück zum Zitat Greaves M (2001) Cancer: the evolutionary legacy. Oxford University Press, Oxford Greaves M (2001) Cancer: the evolutionary legacy. Oxford University Press, Oxford
3.
Zurück zum Zitat Nixon R (1971) Remarks on signing the National Cancer Act of 1971 Nixon R (1971) Remarks on signing the National Cancer Act of 1971
4.
Zurück zum Zitat Nixon R (1971) Annual message to the congress on the state of the union Nixon R (1971) Annual message to the congress on the state of the union
5.
7.
Zurück zum Zitat Erren TC (2005) Could visible light contribute to the development of leukaemia and other cancers in children? Med Hypotheses 64(4):864–871PubMedCrossRef Erren TC (2005) Could visible light contribute to the development of leukaemia and other cancers in children? Med Hypotheses 64(4):864–871PubMedCrossRef
8.
Zurück zum Zitat Rothschild BM, Tanke DH, Helbling M 2nd, Martin LD (2003) Epidemiologic study of tumors in dinosaurs. Naturwissenschaften 90(11):495–500PubMedCrossRef Rothschild BM, Tanke DH, Helbling M 2nd, Martin LD (2003) Epidemiologic study of tumors in dinosaurs. Naturwissenschaften 90(11):495–500PubMedCrossRef
10.
Zurück zum Zitat Lichtenstein P, Nils V, Holm PK, Verkasalo AI, Kaprio J, Koskenvuo M, Pukkala E, Skytthe A, Hemminki K (2000) Environmental and heritable factors in the causation of cancer—analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 343(2):78–85PubMedCrossRef Lichtenstein P, Nils V, Holm PK, Verkasalo AI, Kaprio J, Koskenvuo M, Pukkala E, Skytthe A, Hemminki K (2000) Environmental and heritable factors in the causation of cancer—analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 343(2):78–85PubMedCrossRef
11.
Zurück zum Zitat Erren TC (2002) Preventive research and interventive research: in favour of to act rather than to react. Med Hypotheses 59(2):215–222PubMedCrossRef Erren TC (2002) Preventive research and interventive research: in favour of to act rather than to react. Med Hypotheses 59(2):215–222PubMedCrossRef
12.
Zurück zum Zitat Horrobin DF (2003) Are large clinical trials in rapidly lethal diseases usually unethical? Lancet 361(9358):695–697PubMedCrossRef Horrobin DF (2003) Are large clinical trials in rapidly lethal diseases usually unethical? Lancet 361(9358):695–697PubMedCrossRef
Metadaten
Titel
What Do We Know 40 Years After Nixon Declared the ‘War on Cancer’? On the Origin, Prevention and Treatment of Cancer
Publikationsdatum
01.12.2012
Erschienen in
Journal of Cancer Education / Ausgabe 4/2012
Print ISSN: 0885-8195
Elektronische ISSN: 1543-0154
DOI
https://doi.org/10.1007/s13187-012-0411-7

Weitere Artikel der Ausgabe 4/2012

Journal of Cancer Education 4/2012 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.